Ar/miR-221/IGF-1 Pathway Mediates the Pathogenesis of Androgenetic Alopecia

    January 2022 in “ Social Science Research Network ”
    Kaitao Li, Yan Sun, Shizhao Liu, Shizhao Liu, Qian Qu, Jin Wang, Ruosi Chen, Zhexiang Fan, Bingcheng Liu, Xiaoyan Mao, Zhiqi Hu, Yong Miao
    Image of study
    TLDR The Ar/miR-221/IGF-1 pathway is involved in male pattern baldness, with miR-221 potentially being a new target for treatment.
    The study "Ar/miR-221/IGF-1 Pathway Mediates the Pathogenesis of Androgenetic Alopecia" involved 23 male patients with androgenetic alopecia (AGA) and 5 healthy male controls. The research found that dihydrotestosterone (DHT), the main cause of AGA, binds to the androgen receptor (AR) and triggers the transcription of genes responsible for AGA. The study discovered that AR predominantly expressed in dermal papilla cells (DPCs) and dermal sheath cells (DSCs) in hair follicles directly promotes the transcription of miR-221, which significantly suppresses hair growth and proliferation of DPCs and DSCs. The miR-221 directly targets IGF-1 to inactivate the MAPK pathway and PI3K/AKT pathway in DPCs and DSCs. The study suggests that miR-221 is a novel biomarker and/or therapeutic target for AGA.
    Discuss this study in the Community →

    Research cited in this study

    19 / 19 results

    Related Community Posts Join

    6 / 1000+ results

      community Fevipiprant 2019!

       17 upvotes 8 years ago
      The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.
      Diffuse hair loss and scalp biopsies

      community Diffuse hair loss and scalp biopsies

      in Research  692 upvotes 3 months ago
      Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

    Similar Research

    6 / 1000+ results